OSLO,
Norway, June 1, 2022 /PRNewswire/ -- Navamedic ASA
("Navamedic" or the "Company") (OSE: NAVA) today announces that it
has completed the acquisition of Impolin AB, as announced by the
Company on 5 May 2022.
As partial settlement of the purchase price for the acquisition,
the board of directors of Navamedic has today, on 1 June 2022, resolved to increase the Company's
share capital with NOK 597,266.58 by
issuance of 807,117 new shares in the Company to Agnvicen AB, being
the seller of Impolin AB, each with a nominal value of NOK 0.74. The consideration shares were issued at
a subscription price of NOK 29.7757
per consideration share upon conversion of an account receivable of
NOK 24,032,500. The subscription
price for the consideration shares is equal to the volume weighted
average share price of the Company's shares on the Oslo Stock
Exchange during the period from (but not including) 31 December 2021 to (but not including) the
closing date of the acquisition. The share capital increase was
resolved by the board of directors under the authorisation to
increase the Company's share capital granted by the annual general
meeting held on 3 June 2021. To
complete Navamedic's obligations pursuant to the share purchase
agreement for the acquisition of Impolin AB, the preferential right
of the existing shareholders was deviated from. The consideration
shares are subject to a lock-up period of 24 months on the terms
and conditions of the share purchase agreement.
Following the registration of the share capital increase
pertaining to the consideration shares with the Norwegian Register
of Business Enterprises (Nw. Foretaksregisteret), the share capital
of Navamedic will be NOK
12,748,554.98, divided into 17,227,777 shares, each with a
nominal value of NOK 0.74.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO,
Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic ASA:
Navamedic ASA is a Nordic full-service provider of high-quality
products to hospitals and through pharmacies. Navamedic meets the
specific needs of patients and consumers by leveraging its highly
scalable market access platform, leading category competence and
local knowledge. Navamedic is present in all the Nordic countries,
the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered
in Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA).
For more information, please visit www.navamedic.com.
This information is subject of the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.